These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2004-000140-25 A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of 2 mg/kg Bolus Plus 24-hour 0.05 mg/kg/hr Infusion Pexelizumab in Patients Undergoing Coronary Artery Bypass Graftin... 2006-02-01 due-trials
Not reported 2004-000142-20 A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PC... 2006-08-08 due-trials
Not reported 2004-000485-13 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of One-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Admini... 2010-09-19 due-trials
Reported results 2004-000486-35 A multicentre, double-blind, randomised, active controlled, parallel group, noninferiority study comparing 75mg risedronate dosed on two consecutive days monthly with 5mg daily risedronate in the trea... 2007-02-28 due-trials
Reported results 2004-001222-25 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 52-week Study to Evaluate the Efficacy ans Safety of Transdermal Patches Delivering 150 or 300 microgram/day Testosterone i... 2007-01-09 due-trials
Reported results 2004-004077-29 A Double-blind, Randomized, Multicenter, Active-control, 56-day Study with a 28-day Follow-up to Assess the Efficacy and Safety of RDP58 200 mg/day plus Mesalazine 2.4 g/day and RDP58 600 mg/day plus ... 2005-11-18 due-trials
Listed as ongoing, but also has a completion date 2005-002785-10 A Phase III, Multicenter, Double-Blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly with 5 mg Risedronate Daily in the Treatment of Postme... 2008-03-18 bad-data
Reported results 2005-003033-41 A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized... 2009-09-22 due-trials
Reported results 2005-005207-42 A study to assess the efficacy of a combination of natural plant extracts in natural colds. 2006-04-13 due-trials
Reported results 2006-001179-39 A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Women w... 2008-06-24 due-trials
Reported results 2006-001310-32 A double-blind, randomized, 6-week, parallel-group clinical trial to assess the safety and efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) fo... 2007-06-25 due-trials
Not reported 2006-002216-10 A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 7605... 2007-12-20 due-trials
Not reported 2007-001521-98 A Non-inferiority Comparison of 35mg Delayed-release Risedronate, Administered Once-weekly Either Before or After Breakfast, and 5mg Immediate-release Risedronate, Administered Once-daily Before Break... 2010-04-28 due-trials
Not reported 2007-002145-21 A Phase II, Randomized, Placebo-controlled Study of ATI-7505 in Patients with Chronic Idiopathic Constipation 2008-07-03 due-trials
Reported results 2007-005008-41 A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-controlled, 58-day, Dose-ranging Study of ATI-7505 in Patients with Postprandial Distress Syndrome 2008-07-03 due-trials
Not reported 2007-005702-49 A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Chil... 2011-03-08 due-trials
Reported results 2011-002443-10 A Randomized, Open-Label, Single-Dose, Parallel Group Study to Evaluate the Utility of Magnetic Resonance Imaging (MRI) in Demonstrating the Nasal Decongestant Efficacy of an Active Control (Vicks® Si... 2012-03-21 due-trials
Reported results 2013-004524-11 A 2-arm, randomised, single - (investigator) blind, controlled, parallel design study in common cold sufferers experiencing cough and nasal congestion to assess the effects of Vicks® VapoRub® (VVR) on... 2015-05-14 due-trials
Reported results 2013-005006-66 A 2-arm, randomised, single - (Investigator) blind, controlled, parallel design study in common cold sufferers experiencing nasal congestion to assess the speed of action of Vicks® VapoRub® (VVR) 2014-03-11 due-trials